Verastem, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VSTM research report →
Companywww.verastem.com
Verastem, Inc. , a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
- CEO
- Daniel W. Paterson
- IPO
- 2012
- Employees
- 78
- HQ
- Needham, MA, US
Price Chart
Valuation
- Market Cap
- $286.27M
- P/E
- -2.09
- P/S
- 5.77
- P/B
- 4.96
- EV/EBITDA
- -0.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 83.75%
- Op Margin
- -344.56%
- Net Margin
- -391.16%
- ROE
- -486.41%
- ROIC
- -102.15%
Growth & Income
- Revenue
- $30.91M · 209.14%
- Net Income
- $-209,471,000 · -60.35%
- EPS
- $-3.02 · 17.49%
- Op Income
- $-170,129,000
- FCF YoY
- -31.21%
Performance & Tape
- 52W High
- $11.25
- 52W Low
- $4.01
- 50D MA
- $5.53
- 200D MA
- $7.45
- Beta
- 0.34
- Avg Volume
- 2.10M
Get TickerSpark's AI analysis on VSTM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Paterson Dan | sell | 806 |
| Mar 20, 26 | Calkins Daniel | other | 57 |
| Feb 4, 26 | Paterson Dan | sell | 970 |
| Jan 21, 26 | Calkins Daniel | other | 16,665 |
| Jan 21, 26 | Paterson Dan | other | 213,785 |
| Jan 12, 26 | Paterson Dan | sell | 10,321 |
| Jan 12, 26 | Calkins Daniel | sell | 5,039 |
| Jan 6, 26 | Kauffman Michael | other | 200,000 |
| Dec 24, 25 | Calkins Daniel | sell | 80 |
| Dec 16, 25 | Stuglik Brian M | sell | 592 |
Our VSTM Coverage
We haven't published any research on VSTM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VSTM Report →